Kun Ernest, Kirsten Eva, Bauer Pal I, Ordahl Charles P
Department of Anatomy, School of Medicine, University of California San Francisco Medical Center, San Francisco, CA 94143, USA.
Int J Mol Med. 2006 Feb;17(2):293-300.
Treatment of cells with lysophosphatidyl choline and centrifugal extraction can separate poly (ADP-ribose) synthetase (PARP-1) and DNA synthetase activities, permitting the experimental analysis and comparison of both multienzyme systems. Only PARP-1 is being assayed by our system. Ca(2+) and Mg(2+) have minor activating effects, and added histones are without activating action. Short end-blocked dsDNAs at nM concentrations and spermine at mM concentrations are maximally activating coenzymes of poly (ADP-ribose) synthesis. Comparison of non-proliferating non-malignant cells with rapidly growing cancer cells demonstrates that rates of poly (ADP-ribose) synthesis and DNA synthesis are highest in pre-confluent non-malignant cells and in proliferating cancer cells, and lowest in contact-inhibited non-malignant cells. Rates of poly (ADP-ribose) synthesis correlate with the number of enzymatically activable PARP-1 molecules per cell, determined under Vmax conditions where activity is linearly proportional to enzyme protein. Contact-inhibited non-malignant cells exhibit only trans-ADP-ribosylation that is not affected by ATP, while rapid growth, especially in cancer cells, demonstrates extensive auto-poly (ADP)-ribosylation that is strongly inhibited by ATP at concentrations present in cells exhibiting normal bioenergetics. Rates of mRNA synthesis in non-proliferating non-malignant cells and in cancer cells were indistinguishable, indicating that the differences observed between cellular phenotypes are most likely due to reassembly of PARP-1 molecules in nuclei to homo-dimers (in cancer cells) and hetero-dimers (in non-cancer cells). A specific inhibitor and an inactivator of PARP-1 each inhibit DNA synthesis when intact cancer cells are pretreated with these drugs. Direct addition of these drugs to permeabilized cells performing DNA synthesis has no effect on DNA synthesis. The most striking diagnostic signal for cancer cells is activation of PARP-1 and of DNA synthesis.
用溶血磷脂酰胆碱处理细胞并进行离心提取,可分离聚(ADP - 核糖)合成酶(PARP - 1)和DNA合成酶活性,从而对这两种多酶系统进行实验分析和比较。我们的系统仅检测PARP - 1。Ca(2+)和Mg(2+)具有轻微的激活作用,添加的组蛋白则无激活作用。纳摩尔浓度的短末端封闭双链DNA和毫摩尔浓度的精胺是聚(ADP - 核糖)合成的最大激活辅酶。将非增殖性非恶性细胞与快速生长的癌细胞进行比较表明,聚(ADP - 核糖)合成和DNA合成速率在汇合前的非恶性细胞和增殖性癌细胞中最高,而在接触抑制的非恶性细胞中最低。聚(ADP - 核糖)合成速率与每个细胞中可酶促激活的PARP - 1分子数量相关,该数量是在Vmax条件下测定的,此时活性与酶蛋白呈线性比例。接触抑制的非恶性细胞仅表现出不受ATP影响的反式ADP - 核糖基化,而快速生长,尤其是在癌细胞中,则表现出广泛的自聚(ADP) - 核糖基化,在具有正常生物能量学的细胞中存在的ATP浓度下,这种自聚(ADP) - 核糖基化受到强烈抑制。非增殖性非恶性细胞和癌细胞中的mRNA合成速率没有差异,这表明细胞表型之间观察到的差异很可能是由于PARP - 1分子在细胞核中重新组装成同二聚体(在癌细胞中)和异二聚体(在非癌细胞中)。当完整的癌细胞用这些药物预处理时,PARP - 1的特异性抑制剂和失活剂均会抑制DNA合成。将这些药物直接添加到进行DNA合成的通透细胞中对DNA合成没有影响。癌细胞最显著得诊断信号是PARP - 1的激活和DNA合成的激活。